We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$841M
AUM Growth
-$257M
Cap. Flow
-$256M
Cap. Flow %
-30.4%
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$56.8M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12.1M
3
COGT icon
Cogent Biosciences
COGT
+$9.38M
4
INCY icon
Incyte
INCY
+$7.38M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.34M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$58.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.06M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.4M
4
MNKD icon
MannKind Corp
MNKD
+$3.35M
5
ABBV icon
AbbVie
ABBV
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 15.86%
2 Consumer Staples 0.43%
3 Consumer Discretionary 0.12%
4 Materials 0.09%
5 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMUC.WS
151
CALL
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
$7K ﹤0.01%
+225,187
New +$6.8K
SLS icon
152
CALL
SELLAS Life Sciences
SLS
$1.98B
$4K ﹤0.01%
30
+25
+500% +$7.14K
ARAV
153
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
$3K ﹤0.01%
+33
New +$371
HALO icon
154
Halozyme
HALO
$9.9B
$2K ﹤0.01%
+102
New +$1.98K
ABBV icon
155
AbbVie
ABBV
$465B
– –
-27,559
Closed -$3.03M
ABBV icon
156
PUT
AbbVie
ABBV
$465B
– –
-776
Closed -$7.5M
AGEN
157
CALL
Agenus
AGEN
$275M
– –
-146
Closed -$932K
AGEN
158
PUT
Agenus
AGEN
$275M
– –
-6
Closed -$38K
ALNY icon
159
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-941
Closed -$12M
AQB icon
160
AquaBounty Technologies
AQB
$4.74M
$0 ﹤0.01%
+6
New +$394
BLUE
161
CALL
DELISTED
bluebird bio
BLUE
– –
-328
Closed -$75.7M
BLUE
162
PUT
DELISTED
bluebird bio
BLUE
– –
-37
Closed -$8.64M
BMY icon
163
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-4,225
Closed -$25.9M
CI icon
164
CALL
Cigna
CI
$79.6B
– –
-670
Closed -$13.6M
GILD icon
165
CALL
Gilead Sciences
GILD
$167B
– –
-454
Closed -$3.25M
HALO icon
166
CALL
Halozyme
HALO
$9.9B
– –
-4,950
Closed -$10M
IMMP
167
Immutep
IMMP
$57M
– –
-21,500
Closed -$34K
IONS icon
168
CALL
Ionis Pharmaceuticals
IONS
$9.14B
– –
-1,429
Closed -$7.19M
IONS icon
169
PUT
Ionis Pharmaceuticals
IONS
$9.14B
– –
-1,230
Closed -$6.19M
JAGX icon
170
Jaguar Health
JAGX
$4.74M
– –
0
– -$142K
KZIA
171
Kazia Therapeutics
KZIA
$140M
– –
-7,333
Closed –
CYPH
172
Cypherpunk Technologies Inc
CYPH
$65.4M
– –
-8,935
Closed -$558K
OCGN icon
173
Ocugen
OCGN
$420M
– –
-15,918
Closed -$1.96M
AIXC
174
AIxCrypto Holdings Inc
AIXC
$16.7M
– –
-3
Closed -$118K
RDHL
175
Redhill Biopharma
RDHL
$4.44M
– –
-21
Closed -$110K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sabby Management withdrew a net $256M in Q1 2018, closing 75 positions and reducing 47 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $6.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 12% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Biogen worth $50.1M.

  • Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
  • Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
  • Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
  • Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
  • Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
  • Sabby Management opened 70 new positions and closed 75 in Q1 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.